Abstract 444P
Background
In 2017, SURC was introduced in Victoria Australia responding to broader contexts challenges within the health system. SURC’s a nurse led model of care addressing and identifying gaps within an oncology service to support patients experiencing SACT toxicities during the period of active treatment. In May 2020 the Symptom & Urgent Review Clinic (SURC) commenced in Ballarat’s Regional Integrated Cancer Centre. (BRICC) provides health care in the Victorian Grampians Region covering 48,646 square kilometre area. BRICC provides three outreach cancer services to Stawell, Horsham, and Maryborough.
Methods
SURC provides a streamlined process for Oncology patients receiving SACT access to dedicated oncology nursing and medical staff through a single point of access. Patients access SURC from start of treatment, throughout their SACT and 12 weeks after treatment completion. SURC contacts all C1D5 patients, patients discharged from hospital, and shared medical/nursing model of care. SURC referrals were from the medical and nursing oncology team, allied health and other internal and external stakeholders. Patients or their carer could call SURC directly. Workforce challenges in 2022 resulted in SURC setting up a mirrored service supporting BRICC patients in Stawell and Maryborough enabling them to continue having treatment close to home and have their symptoms and toxicities addressed in a timely fashion by an advanced oncology nurse. SURC also became the point of contact for any COVID-related questions and management of patients testing COVID positive.
Results
From May 2020-April 2023 there was 6558 contacts to SURC including telephone calls, clinic presentations, same day ED and day admissions. SURC funding was outpatient WASE 40.52 data activity recorded by IBA. Pre and post SURC data for admitted patients was analysed showing inpatient stay days halved from 686 to 399, reduction in inpatient oncology visits of 104 to 70, as well as readmissions from 4-0.
Conclusions
SURC has improved quality of care and access to specialist nursing and medical advice for patients receiving SACT. SURC provides a single point of access for patients receiving SACT and has also had a significant positive impact on early symptom recognition and management in a timely manner.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Grampians Health Ballarat.
Funding
Has not received any funding.
Disclosure
S. Bartlett: Non-Financial Interests, Personal and Institutional, Member of Board of Directors: CNSA.
Resources from the same session
280P - Radium-223 for patients with metastatic castration-resistant prostate cancer with symptomatic bone metastases progressing after first-line abiraterone or enzalutamide: One institutional experience
Presenter: Keng Man Chiang
Session: Poster Display
Resources:
Abstract
281P - 10-year treatment outcome of prostate cancer patients with 3D conformal radiation: Experience of a single cancer institution in Iran
Presenter: Reyhane Bayani
Session: Poster Display
Resources:
Abstract
282P - Predictors of outcomes in patients with clinically lymph node-positive prostate cancer after definitive radiotherapy
Presenter: Jae-Sung Kim
Session: Poster Display
Resources:
Abstract
283P - Radiotherapy utilization rate and treatment patern of protate cancer at Cipto Mangunkusumo Central General Hospital (RSCM): What we learn from pre-pandemic era
Presenter: Riyan Apriantoni
Session: Poster Display
Resources:
Abstract
284TiP - CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer
Presenter: Nobuaki Matsubara
Session: Poster Display
Resources:
Abstract
292P - Comparative characteristics of early cervical cancer diagnosis methods for Tashkent women
Presenter: Gulnoza Goyibova
Session: Poster Display
Resources:
Abstract
293P - Carboplatin in locally advanced cervical cancer treated with chemoradiation: An alternative to cisplatin
Presenter: Natalia Isabel Valdiviezo Lama
Session: Poster Display
Resources:
Abstract
294P - Concurrent chemoradiation with cisplatin every 3 weeks in locally advanced cervical cancer: A single arm phase II clinical trial
Presenter: Long Nguyen
Session: Poster Display
Resources:
Abstract
295P - A prospective study of dose escalated simultaneous integrated boost in node-positive cervical cancer
Presenter: Ritusha Mishra
Session: Poster Display
Resources:
Abstract
296P - Safety, efficacy, and immunogenicity of therapeutic vaccines for patients with high-grade cervical intraepithelial neoplasia (CIN 2/3) associated with human papillomavirus: A systematic review
Presenter: Caroline Amélia Gonçalves
Session: Poster Display
Resources:
Abstract